$LNZA
LanzaTech Global, Inc. Stock $lnza

$lnza Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000162828023018273 Filed on May 15, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022 Q1
Revenue	$9.646M	$0.00	$0.00
YoY Change
Cost Of Revenue	$7.790M	$60.00K	$53.58K
YoY Change	14439.01%	-69.72%
Gross Profit	$1.860M	-$60.00K	-$53.58K
YoY Change	-3571.44%	-69.72%
Gross Profit Margin	19.28%
Selling, General & Admin	$16.84M	$2.330M	$2.732M
YoY Change	516.29%	211.25%
% of Gross Profit	905.11%
Research & Development	$16.29M		$12.36M
YoY Change	31.75%
% of Gross Profit	875.59%
Depreciation & Amortization	$1.257M		$1.059M
YoY Change	18.7%
% of Gross Profit	67.58%
Operating Expenses	$33.12M	$2.330M	$2.732M
YoY Change	1112.47%	211.25%	241642.48%
Operating Profit	-$32.52M	-$2.390M	-$2.785M
YoY Change	1067.64%	152.45%	247259.86%
Interest Expense	$214.0K	$230.0K	-$757.5K
YoY Change	-128.25%	-56.27%
% of Operating Profit
Other Income/Expense, Net	-$30.18M	$0.00	-$26.00K
YoY Change	115984.62%
Pretax Income	-$62.70M	-$2.160M	-$3.543M
YoY Change	1669.83%	413.32%	314528.95%
Income Tax	$0.00	$250.0K	$0.00
% Of Pretax Income
Net Earnings	-$63.31M	-$2.410M	-$3.543M
YoY Change	1687.1%	472.73%	314528.95%
Net Earnings / Revenue	-656.35%
Basic Earnings Per Share	-$0.58		-$2.85
Diluted Earnings Per Share	-$0.58	-$0.13	-$188.9K
COMMON SHARES
Basic Shares Outstanding	195.5M shares		9.219M shares
Diluted Shares Outstanding	116.5M shares		9.219M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$194.2M	$0.00	$8.320K
YoY Change	2334034.62%	-100.0%	856.32%
Cash & Equivalents	$145.1M	$6.671K	$8.315K
Short-Term Investments	$49.10M
Other Short-Term Assets	$18.69M	$11.16M	$368.1K
YoY Change	4977.57%	3205.48%	214.37%
Inventory		$1.129M
Prepaid Expenses		$190.6K	$368.1K
Receivables	$27.70M
Other Receivables	$0.00
Total Short-Term Assets	$240.6M	$197.3K	$376.4K
YoY Change	63837.07%	-71.02%	219.08%
LONG-TERM ASSETS
Property, Plant & Equipment	$19.79M	$19.69M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$9.835M	$10.56M	$150.0M
YoY Change	-93.44%	-92.96%
Other Assets	$300.0K	$750.0K	$106.7K
YoY Change	181.19%	305.82%
Total Long-Term Assets	$67.31M	$152.3M	$150.1M
YoY Change	-55.16%	1.4%
TOTAL ASSETS
Total Short-Term Assets	$240.6M	$197.3K	$376.4K
Total Long-Term Assets	$67.31M	$152.3M	$150.1M
Total Assets	$308.0M	$152.5M	$150.5M
YoY Change	104.63%	1.08%	127479.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.52M	$2.495M	$68.03K
YoY Change	16835.65%	2816.97%	340.35%
Accrued Expenses	$9.600M	$2.257M	$2.556M
YoY Change	275.57%	882.47%	2456.12%
Deferred Revenue	$3.042M	$3.101M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$34.08M	$6.873M	$3.145M
YoY Change	983.55%	814.78%	3242.85%
LONG-TERM LIABILITIES
Long-Term Debt	$19.40M	$50.00M	$0.00
YoY Change
Other Long-Term Liabilities	$1.591M	$1.591M	$11.63M
YoY Change	-86.32%	-85.35%
Total Long-Term Liabilities	$20.99M	$51.59M	$11.63M
YoY Change	80.49%	375.06%
TOTAL LIABILITIES
Total Short-Term Liabilities	$34.08M	$6.873M	$3.145M
Total Long-Term Liabilities	$20.99M	$51.59M	$11.63M
Total Liabilities	$78.15M	$9.714M	$14.77M
YoY Change	428.9%	-16.34%	15604.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$761.1M	-$8.334M	-$14.28M
YoY Change	5228.73%	-22.4%
Common Stock	$19.00K	$1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$229.8M	-$8.333M	-$14.28M
YoY Change
Total Liabilities & Shareholders Equity	$308.0M	$152.5M	$150.5M
YoY Change	104.63%	1.08%	127479.38%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022 Q1
OPERATING ACTIVITIES
Net Income	-$63.31M	-$2.410M	-$3.543M
YoY Change	1687.1%	472.73%	314528.95%
Depreciation, Depletion And Amortization	$1.257M		$1.059M
YoY Change	18.7%
Cash From Operating Activities	-$33.81M	$0.00	-$344.1K
YoY Change	9726.09%	-100.0%	272982.54%
INVESTING ACTIVITIES
Capital Expenditures	$1.367M		$1.891M
YoY Change	-27.71%
Acquisitions
YoY Change
Other Investing Activities	-$109.2M	$0.00	$9.000K
YoY Change	-1213433.33%
Cash From Investing Activities	-$110.6M	$0.00	$9.000K
YoY Change	-1228611.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$206.5M		0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-$33.81M	0.000	-344.1K
Cash From Investing Activities	-$110.6M	0.000	9.000K
Cash From Financing Activities	$206.5M		0.000
Net Change In Cash	$62.10M	0.000	-335.1K
YoY Change	-18632.96%	-100.0%	-38439.13%
FREE CASH FLOW
Cash From Operating Activities	-$33.81M	$0.00	-$344.1K
Capital Expenditures	$1.367M		$1.891M
Free Cash Flow	-$35.18M		-$2.235M
YoY Change	1473.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001843724
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	lnza	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P0Y
CY2023Q1	lnza	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm	P0Y
CY2023Q1	lnza	Share Based Compensation Arrangement By Share Based Payment Award Options Canceled And Forfeited Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledAndForfeitedWeightedAverageRemainingContractualTerm	P0Y
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-40282
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	LanzaTech Global, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	92-2018969
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	8045 Lamon Avenue
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 400
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Skokie
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	IL
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	60077
CY2023Q1	dei	City Area Code CityAreaCode	847
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	324-2400
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	195451596	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	145118000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	83045000	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	49103000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	0	usd
CY2023Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	9277000	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	11695000	usd
CY2023Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	18460000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	18000000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	18689000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	11157000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	240647000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	123897000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19794000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19689000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6437000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6969000	usd
CY2023Q1	us-gaap	Equity Method Investments EquityMethodInvestments	9835000	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	10561000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni And Without Readily Determinable Fair Value EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue	14990000	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni And Without Readily Determinable Fair Value EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue	14990000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	300000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	750000	usd
CY2023Q1	us-gaap	Derivative Instruments And Hedges Noncurrent DerivativeInstrumentsAndHedgesNoncurrent	15954000	usd
CY2022Q4	us-gaap	Derivative Instruments And Hedges Noncurrent DerivativeInstrumentsAndHedgesNoncurrent	0	usd
CY2023Q1	us-gaap	Assets Assets	307957000	usd
CY2022Q4	us-gaap	Assets Assets	176856000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	11522000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7455000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4143000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4502000	usd
CY2023Q1	lnza	Simple Agreement For Future Equity Liability SimpleAgreementForFutureEquityLiability	0	usd
CY2022Q4	lnza	Simple Agreement For Future Equity Liability SimpleAgreementForFutureEquityLiability	28986000	usd
CY2023Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	9919000	usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	4108000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3042000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3101000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4644000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7031000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	807000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	798000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	34077000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	55981000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5939000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6615000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	10171000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	10760000	usd
CY2023Q1	lnza	Fixed Maturity Consideration Noncurrent FixedMaturityConsiderationNoncurrent	6967000	usd
CY2022Q4	lnza	Fixed Maturity Consideration Noncurrent FixedMaturityConsiderationNoncurrent	0	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	19400000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	50000000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1591000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1591000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	78145000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	124947000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	130133670	shares
CY2023Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2023Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	129148393	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	129148393	shares
CY2023Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	480631000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	158918093	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	195451596	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	195451596	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10422051	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10422051	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	19000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	988188000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	24782000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2691000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2740000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-761086000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-456245000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	229812000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-428722000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	307957000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	176856000	usd
CY2023Q1	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	1088000	usd
CY2022Q1	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	0	usd
CY2023Q1	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	973000	usd
CY2022Q1	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	654000	usd
CY2023Q1	us-gaap	Revenues Revenues	9646000	usd
CY2022Q1	us-gaap	Revenues Revenues	7857000	usd
CY2023Q1	lnza	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization Collaborative Arrangements CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortizationCollaborativeArrangements	407000	usd
CY2022Q1	lnza	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization Collaborative Arrangements CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortizationCollaborativeArrangements	0	usd
CY2023Q1	lnza	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization Related Party CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortizationRelatedParty	41000	usd
CY2022Q1	lnza	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization Related Party CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortizationRelatedParty	69000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16286000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12361000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	1257000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	1059000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	16835000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5078000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	42168000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	24327000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-32522000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-16470000	usd
CY2023Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	214000	usd
CY2022Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	0	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-30396000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-26000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-30182000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-26000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-62704000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-16496000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	lnza	Income Loss From Equity Method Investments And Gain On Dilution Of Investment IncomeLossFromEquityMethodInvestmentsAndGainOnDilutionOfInvestment	-608000	usd
CY2022Q1	lnza	Income Loss From Equity Method Investments And Gain On Dilution Of Investment IncomeLossFromEquityMethodInvestmentsAndGainOnDilutionOfInvestment	-282000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-63312000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-16778000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-49000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-28000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-63361000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16806000	usd
CY2023Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	4117000	usd
CY2022Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	9523000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-67429000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-26301000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.58
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.58
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.85
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.85
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	116530963	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	116530963	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9219499	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9219499	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	129148393	shares
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	480631000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-428722000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3505000	usd
CY2023Q1	lnza	Adjustments To Additional Paid In Capital Repurchase Of Equity Instruments AdjustmentsToAdditionalPaidInCapitalRepurchaseOfEquityInstruments	7650000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-63312000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	746000	usd
CY2023Q1	lnza	Temporary Equity Shares Conversion Of Convertible Securities TemporaryEquitySharesConversionOfConvertibleSecurities	594309	shares
CY2023Q1	lnza	Temporary Equity Value Conversion Of Convertible Securities TemporaryEquityValueConversionOfConvertibleSecurities	5890000	usd
CY2023Q1	us-gaap	Temporary Equity Accretion Of Dividends TemporaryEquityAccretionOfDividends	241529000	usd
CY2023Q1	us-gaap	Dividends Preferred Stock Paidinkind DividendsPreferredStockPaidinkind	241529000	usd
CY2023Q1	lnza	Temporary Equity Conversion Of Preferred Stock Into Common Stock TemporaryEquityConversionOfPreferredStockIntoCommonStock	129742702	shares
CY2023Q1	lnza	Temporary Equity Value Conversion Of Preferred Stock Into Common Stock TemporaryEquityValueConversionOfPreferredStockIntoCommonStock	728050000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	728050000	usd
CY2023Q1	lnza	Stock Issued During Period Value Reverse Recapitalization StockIssuedDuringPeriodValueReverseRecapitalization	236973000	usd
CY2023Q1	lnza	Adjustments To Additional Paid In Capital Issuance And Reclassification To Equity Classified Warrants AdjustmentsToAdditionalPaidInCapitalIssuanceAndReclassificationToEquityClassifiedWarrants	1800000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-49000	usd
CY2023Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2023Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	229812000	usd
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	129148393	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	480631000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-354917000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	738000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-16778000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-28000	usd
CY2022Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	129148393	shares
CY2022Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	480631000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-370978000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-63312000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-16778000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3505000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	738000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-20979000	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-60000	usd
CY2023Q1	lnza	Loss On Change In Fair Value Of Forward Purchase Option And Fixed Maturity Consideration LossOnChangeInFairValueOfForwardPurchaseOptionAndFixedMaturityConsideration	51109000	usd
CY2022Q1	lnza	Loss On Change In Fair Value Of Forward Purchase Option And Fixed Maturity Consideration LossOnChangeInFairValueOfForwardPurchaseOptionAndFixedMaturityConsideration	0	usd
CY2023Q1	us-gaap	Provision For Other Losses ProvisionForOtherLosses	800000	usd
CY2022Q1	us-gaap	Provision For Other Losses ProvisionForOtherLosses	0	usd
CY2023Q1	us-gaap	Depreciation Depreciation	1257000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	1059000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	532000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	438000	usd
CY2023Q1	lnza	Noncash Recognition Of Licensing Revenue NoncashRecognitionOfLicensingRevenue	553000	usd
CY2022Q1	lnza	Noncash Recognition Of Licensing Revenue NoncashRecognitionOfLicensingRevenue	540000	usd
CY2023Q1	lnza	Income Loss From Equity Method Investments And Gain On Dilution Of Investment IncomeLossFromEquityMethodInvestmentsAndGainOnDilutionOfInvestment	-608000	usd
CY2022Q1	lnza	Income Loss From Equity Method Investments And Gain On Dilution Of Investment IncomeLossFromEquityMethodInvestmentsAndGainOnDilutionOfInvestment	-282000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	171000	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-65000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1618000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-808000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	408000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	4792000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	8593000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1807000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1692000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1113000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-60000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	299000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-667000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-491000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-188000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1548000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33810000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18118000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1367000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1891000	usd
CY2023Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	49103000	usd
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	usd
CY2023Q1	us-gaap	Payments For Derivative Instrument Investing Activities PaymentsForDerivativeInstrumentInvestingActivities	60096000	usd
CY2022Q1	us-gaap	Payments For Derivative Instrument Investing Activities PaymentsForDerivativeInstrumentInvestingActivities	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-110566000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1891000	usd
CY2023Q1	lnza	Proceeds From Issuance Or Sale Of Equity Excluding Warrant Exercises ProceedsFromIssuanceOrSaleOfEquityExcludingWarrantExercises	746000	usd
CY2022Q1	lnza	Proceeds From Issuance Or Sale Of Equity Excluding Warrant Exercises ProceedsFromIssuanceOrSaleOfEquityExcludingWarrantExercises	7000	usd
CY2023Q1	lnza	Proceeds From The Business Combination Net Financing Activities ProceedsFromTheBusinessCombinationNetFinancingActivities	213381000	usd
CY2022Q1	lnza	Proceeds From The Business Combination Net Financing Activities ProceedsFromTheBusinessCombinationNetFinancingActivities	0	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	7650000	usd
CY2022Q1	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	206477000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	62101000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-20002000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	83710000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	128732000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-25000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-103000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	145786000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	108627000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	234000	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	60000	usd
CY2023Q1	lnza	Reclassification Of Capitalized Costs Related To The Business Combination To Equity ReclassificationOfCapitalizedCostsRelatedToTheBusinessCombinationToEquity	1514000	usd
CY2022Q1	lnza	Reclassification Of Capitalized Costs Related To The Business Combination To Equity ReclassificationOfCapitalizedCostsRelatedToTheBusinessCombinationToEquity	0	usd
CY2023Q1	lnza	Cashless Conversion Of Warrants On Preferred Shares CashlessConversionOfWarrantsOnPreferredShares	5890000	usd
CY2022Q1	lnza	Cashless Conversion Of Warrants On Preferred Shares CashlessConversionOfWarrantsOnPreferredShares	0	usd
CY2023Q1	lnza	Recognition Of Public And Private Warrant Liabilities In The Business Combination RecognitionOfPublicAndPrivateWarrantLiabilitiesInTheBusinessCombination	4624000	usd
CY2022Q1	lnza	Recognition Of Public And Private Warrant Liabilities In The Business Combination RecognitionOfPublicAndPrivateWarrantLiabilitiesInTheBusinessCombination	0	usd
CY2023Q1	lnza	Reclassification Of Am Safe Warrant To Equity ReclassificationOfAmSafeWarrantToEquity	1800000	usd
CY2022Q1	lnza	Reclassification Of Am Safe Warrant To Equity ReclassificationOfAmSafeWarrantToEquity	0	usd
CY2023Q1	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	29730000	usd
CY2022Q1	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	usd
CY2023Q1	lnza	Conversion Of Preferred Stock Shares Converted ConversionOfPreferredStockSharesConverted	722160000	usd
CY2022Q1	lnza	Conversion Of Preferred Stock Shares Converted ConversionOfPreferredStockSharesConverted	0	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	Description of the Business<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LanzaTech Global, Inc., formerly known as AMCI Acquisition Corp. II (“AMCI”) prior to February 8, 2023 (the “Closing Date”) was incorporated as a Delaware Corporation on January 28, 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2022, LanzaTech NZ, Inc. ("Legacy LanzaTech") entered into an Agreement and Plan of Merger (the “Merger Agreement”) with AMCI and AMCI Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of AMCI (“Merger Sub”). On February 8, 2023, Legacy LanzaTech completed its business combination with AMCI by which the Merger Sub merged with and into Legacy LanzaTech, with Legacy LanzaTech continuing as the surviving corporation and as a wholly owned subsidiary of AMCI (the “Business Combination”). The reporting entity is LanzaTech Global, Inc. and its subsidiaries (collectively referred to herein as “the Company” or "LanzaTech"). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is headquartered in Skokie, Illinois. The Company is a nature-based carbon refining company that transforms waste carbon into the chemical building blocks for consumer goods such as sustainable fuels, fabrics, and packaging that people use in their daily lives. The Company’s customers leverage its proven proprietary gas fermentation technology platform to convert certain feedstock, including waste carbon gases, into sustainable fuels and chemicals such as ethanol.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> performs related services such as feasibility studies, engineering services, and research and development ("R&D") in biotechnology for commercial and government customers. The Company also purchases the low carbon chemicals produced at customer facilities employing the Company’s technology and sells it under the brand name CarbonSmart.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, the Company’s partners operate three commercial scale waste-to-gas ethanol plants in China, with others currently in development in various countries compared to two commercial scale waste-to-gas ethanol plants in China as of March 31, 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reclassified its warrants on preferred shares as of December 31, 2022 from other accrued liabilities to warrants on the condensed consolidated balance sheet to conform with current period presentation. This reclassification resulted in a decrease to other accrued liabilities and corresponding increase to warrants of $2,119 as of December 31, 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Business Combination, the Company’s common stock trades under the ticker symbol “LNZA” and its Public Warrants trade under the ticker symbol “LNZAW” on the Nasdaq Stock Market. Prior to the consummation of the Business Combination, the Company’s common shares were listed on Nasdaq Stock Market under the symbol “AMCI.”</span></div>
CY2023Q1	lnza	Commercial Plants Operated CommercialPlantsOperated	3	plant
CY2022Q1	lnza	Commercial Plants Operated CommercialPlantsOperated	2	plant
CY2023Q1	lnza	Voting Rights Stock Percentage VotingRightsStockPercentage	0.853
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	145118000	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	49103000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-761086000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33810000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-63312000	usd
CY2023Q1	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	153285000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include fair value of equity awards granted to both employees and non-employees, revenue recognized over time, AM SAFE, Brookfield SAFE, AM SAFE warrants, the Forward Purchase Agreement and the Private Placement Warrants.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the percentage of completion for both input and output methods to recognize revenue over time for certain contracts with customers. Under the output method, the Company exercises judgment and estimation when determining the percentage of completion against the total transaction price initially estimated. Under the input method, the Company exercises judgment and estimation when selecting the most indicative measure of such performance. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our arrangements provide fixed consideration, however, when there are variable consideration elements, the Company estimates the transaction price and whether revenue should be constrained. Significant estimates and judgments are also used when a material right is provided to the customer. In these instances, the Company estimates the stand-alone selling price and apportions the total transaction price to this material right. Refer to the Revenue Recognition section in Note 2 hereunder.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in facts and circumstances or additional information may result in revised estimates, and actual results may differ from these estimates.</span></div>
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	145118000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	83045000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	145118000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	83045000	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	668000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	665000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	145786000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	83710000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1851000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1051000	usd
CY2023Q1	lnza	Share Price Trigger SharePriceTrigger	3.00
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue generated from the Company’s customers outside of the United States for the three months ended March 31, 2023 and 2022 was approximately 62% in each of the periods presented.</span></div>As of March 31, 2023 and December 31, 2022, approximately 41% and 35%, respectively, of trade accounts receivable and unbilled accounts receivable were due from customers located outside the United States.
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	196222737	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	12574200	shares
CY2023Q1	lnza	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	4.3747
CY2023Q1	us-gaap	Recapitalization Costs RecapitalizationCosts	7223000	usd
CY2023Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	196222737	shares
CY2023Q1	lnza	Sale Of Stock Number Of Shares Issued In Transaction Percentage SaleOfStockNumberOfSharesIssuedInTransactionPercentage	1
CY2023Q1	lnza	Cash Acquired Through Reverse Recapitalization CashAcquiredThroughReverseRecapitalization	64090000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	155000000	usd
CY2023Q1	lnza	Payments Of Reverse Recapitalization Transaction Costs PaymentsOfReverseRecapitalizationTransactionCosts	5709000	usd
CY2023Q1	lnza	Reverse Recapitalization Net ReverseRecapitalizationNet	213381000	usd
CY2023Q1	lnza	Cash Acquired Through Reverse Recapitalization CashAcquiredThroughReverseRecapitalization	64090000	usd
CY2023Q1	lnza	Reverse Capitalization Public Warrants And Private Placement Warrants Recorded On The Closing Date ReverseCapitalizationPublicWarrantsAndPrivatePlacementWarrantsRecordedOnTheClosingDate	4624000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	155000000	usd
CY2023Q1	lnza	Reverse Capitalization Conversion Of The Amsafe ReverseCapitalizationConversionOfTheAMSAFE	29730000	usd
CY2023Q1	lnza	Payments Transaction Costs Allocated To Equity PaymentsTransactionCostsAllocatedToEquity	7223000	usd
CY2023Q1	lnza	Proceeds From Reverse Recapitalization Transaction ProceedsFromReverseRecapitalizationTransaction	236973000	usd
CY2023Q1	lnza	Reverse Recapitalization Shares Held By Pipe And Public Stockholders ReverseRecapitalizationSharesHeldByPIPEAndPublicStockholders	3000	usd
CY2023Q1	lnza	Additional Paid In Capital From Reverse Recapitalization AdditionalPaidInCapitalFromReverseRecapitalization	236970000	usd
CY2023Q1	lnza	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	4.3747
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-63312000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-16778000	usd
CY2023Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	4117000	usd
CY2022Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	9523000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-67429000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-26301000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	116530963	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	116530963	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9219499	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9219499	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.58
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.58
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.85
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.85
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	36012752	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	149459933	shares
CY2023Q1	us-gaap	Preferred Stock Convertible Conversion Ratio PreferredStockConvertibleConversionRatio	1
CY2023Q1	us-gaap	Temporary Equity Accretion Of Dividends TemporaryEquityAccretionOfDividends	241529000	usd
CY2023Q1	lnza	Dividends Denominator DividendsDenominator	10	denominator
CY2023Q1	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	24152942	shares
CY2023Q1	us-gaap	Revenues Revenues	9646000	usd
CY2022Q1	us-gaap	Revenues Revenues	7857000	usd
CY2023Q1	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	1088000	usd
CY2022Q1	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	0	usd
CY2023Q1	us-gaap	Revenues Revenues	9646000	usd
CY2022Q1	us-gaap	Revenues Revenues	7857000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	18000000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3101000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	10760000	usd
CY2023Q1	lnza	Contract With Customer Asset Current Additions To Unbilled Accounts Receivable ContractWithCustomerAssetCurrentAdditionsToUnbilledAccountsReceivable	11241000	usd
CY2023Q1	lnza	Contract With Customer Asset Current Reclassified To Receivable ContractWithCustomerAssetCurrentReclassifiedToReceivable	10833000	usd
CY2023Q1	lnza	Contract With Customer Asset Current Foreign Currency Translation Adjustment ContractWithCustomerAssetCurrentForeignCurrencyTranslationAdjustment	52000	usd
CY2023Q1	lnza	Contract With Customer Liability Noncurrent Foreign Currency Translation Adjustment ContractWithCustomerLiabilityNoncurrentForeignCurrencyTranslationAdjustment	83000	usd
CY2023Q1	lnza	Contract With Customer Liability Current Reclassification From Noncurrent ContractWithCustomerLiabilityCurrentReclassificationFromNoncurrent	672000	usd
CY2023Q1	lnza	Contract With Customer Liability Noncurrent Reclassification To Current ContractWithCustomerLiabilityNoncurrentReclassificationToCurrent	672000	usd
CY2023Q1	lnza	Contract With Customer Liability Current Revenue Recognized ContractWithCustomerLiabilityCurrentRevenueRecognized	731000	usd
CY2023Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	18460000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3042000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	10171000	usd
CY2023Q1	us-gaap	Billed Contract Receivables BilledContractReceivables	9277000	usd
CY2022Q4	us-gaap	Billed Contract Receivables BilledContractReceivables	11695000	usd
CY2023Q1	lnza	Revenue Remaining Performance Obligation Current Amount RevenueRemainingPerformanceObligationCurrentAmount	3042000	usd
CY2022Q4	lnza	Revenue Remaining Performance Obligation Current Amount RevenueRemainingPerformanceObligationCurrentAmount	3101000	usd
CY2023Q1	lnza	Revenue Remaining Performance Obligation Noncurrent Amount RevenueRemainingPerformanceObligationNoncurrentAmount	10171000	usd
CY2022Q4	lnza	Revenue Remaining Performance Obligation Noncurrent Amount RevenueRemainingPerformanceObligationNoncurrentAmount	10760000	usd
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	13213000	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	13861000	usd
CY2023Q1	us-gaap	Debt Securities Unrealized Gain Loss DebtSecuritiesUnrealizedGainLoss	0	usd
CY2023Q1	us-gaap	Equity Method Investments EquityMethodInvestments	9835000	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	10561000	usd
CY2023Q1	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	14990000	usd
CY2022Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	14990000	usd
CY2023Q1	us-gaap	Investments Investments	24825000	usd
CY2022Q4	us-gaap	Investments Investments	25551000	usd
CY2021Q2	lnza	Number Of Rounds Of Investments NumberOfRoundsOfInvestments	2	investment_round
CY2022	us-gaap	Equity Method Investment Other Than Temporary Impairment EquityMethodInvestmentOtherThanTemporaryImpairment	0	usd
CY2023Q1	us-gaap	Equity Method Investment Other Than Temporary Impairment EquityMethodInvestmentOtherThanTemporaryImpairment	0	usd
CY2022Q1	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	0	usd
CY2023Q1	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	0	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	19400000	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	985278	shares
CY2023Q1	lnza	Temporary Equity Shares Conversion Of Convertible Securities TemporaryEquitySharesConversionOfConvertibleSecurities	594309	shares
CY2023Q1	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares	5890000	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.91
CY2023Q1	lnza	Fixed Maturity Consideration Noncurrent FixedMaturityConsiderationNoncurrent	6967000	usd
CY2022Q4	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	50000000	usd
CY2022Q4	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	50000000	usd
CY2023Q1	us-gaap	Foreign Earnings Repatriated ForeignEarningsRepatriated	0	usd
CY2022Q1	us-gaap	Foreign Earnings Repatriated ForeignEarningsRepatriated	0	usd
CY2023Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2022Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q1	lnza	Number Of Share Based Stock Schemes NumberOfShareBasedStockSchemes	5	scheme
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14661000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.48
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y9M18D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	58565000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	14661000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.48
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y9M18D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	58565000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	11203000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.44
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y1M24D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	45204000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	259000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.97
	lnza	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue1	34000	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	472000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.59
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1827000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	93000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1180
CY2023Q1	lnza	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAggregateIntrinsicValue	673000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14355000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.63
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y9M21D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	33903000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	14355000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.63
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y9M21D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	33903000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	11303000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.44
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y3M
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	27650000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	764000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	738000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	4321000	usd
CY2023Q1	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	973000	usd
CY2022Q1	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	654000	usd
CY2022Q4	lnza	Note Receivable Commitment To Purchase NoteReceivableCommitmentToPurchase	5500000	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.0575
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	316250	shares
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	130133670	shares
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	130133670	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	129148393	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	129148393	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	129148393	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	129148393	shares
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	480631000	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	480631000	usd
CY2023Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	1
CY2023Q1	us-gaap	Temporary Equity Accretion Of Dividends TemporaryEquityAccretionOfDividends	241529000	usd
CY2023Q1	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	24152942	shares

Files In Submission

Name	View Source	Status
0001628280-23-018273-index-headers.html	Edgar Link	pending
0001628280-23-018273-index.html	Edgar Link	pending
0001628280-23-018273.txt	Edgar Link	pending
0001628280-23-018273-xbrl.zip	Edgar Link	pending
a311.htm	Edgar Link	pending
a312.htm	Edgar Link	pending
a321.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
lnza-20230331.htm	Edgar Link	pending
lnza-20230331.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
lnza-20230331_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
lnza-20230331_def.xml	Edgar Link	unprocessable
lnza-20230331_pre.xml	Edgar Link	unprocessable
lnza-20230331_htm.xml	Edgar Link	completed
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
lnza-20230331_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LNZA
LanzaTech Global, Inc. Stock $lnza

2023 Q1 Form 10-Q Financial Statement

#000162828023018273 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LNZA LanzaTech Global, Inc. Stock $lnza

2023 Q1 Form 10-Q Financial Statement

#000162828023018273 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LNZA
LanzaTech Global, Inc. Stock $lnza